Vitrolife AB (publ)
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware … Read more
Vitrolife AB (publ) (VTRLY) - Net Assets
Latest net assets as of December 2025: $7.89 Billion USD
Based on the latest financial reports, Vitrolife AB (publ) (VTRLY) has net assets worth $7.89 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.12 Billion) and total liabilities ($3.23 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.89 Billion |
| % of Total Assets | 70.97% |
| Annual Growth Rate | 20.35% |
| 5-Year Change | -48.54% |
| 10-Year Change | 673.73% |
| Growth Volatility | 134.74 |
Vitrolife AB (publ) - Net Assets Trend (2002–2025)
This chart illustrates how Vitrolife AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vitrolife AB (publ) (2002–2025)
The table below shows the annual net assets of Vitrolife AB (publ) from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.89 Billion | -42.12% |
| 2024-12-31 | $13.64 Billion | +7.22% |
| 2023-12-31 | $12.72 Billion | -24.00% |
| 2022-12-31 | $16.74 Billion | +9.12% |
| 2021-12-31 | $15.34 Billion | +660.57% |
| 2020-12-31 | $2.02 Billion | +12.20% |
| 2019-12-31 | $1.80 Billion | +20.15% |
| 2018-12-31 | $1.50 Billion | +21.78% |
| 2017-12-31 | $1.23 Billion | +20.41% |
| 2016-12-31 | $1.02 Billion | +20.76% |
| 2015-12-31 | $844.97 Million | +20.27% |
| 2014-12-31 | $702.57 Million | +117.78% |
| 2013-12-31 | $322.60 Million | +15.63% |
| 2012-12-31 | $278.98 Million | -18.88% |
| 2011-12-31 | $343.90 Million | +5.38% |
| 2010-12-31 | $326.33 Million | +4.57% |
| 2009-12-31 | $312.07 Million | +6.73% |
| 2008-12-31 | $292.39 Million | +15.39% |
| 2007-12-31 | $253.38 Million | +14.84% |
| 2006-12-31 | $220.64 Million | +25.04% |
| 2005-12-31 | $176.45 Million | +17.18% |
| 2004-12-31 | $150.57 Million | +4.98% |
| 2003-12-31 | $143.44 Million | +28.76% |
| 2002-12-31 | $111.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vitrolife AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5897.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00 Million | 0.35% |
| Other Components | $14.62 Billion | 185.20% |
| Total Equity | $7.89 Billion | 100.00% |
Vitrolife AB (publ) Competitors by Market Cap
The table below lists competitors of Vitrolife AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ola Electric Mobility Ltd
NSE:OLAELEC
|
$1.29 Billion |
|
SIX FLAGS E.
F:6FE0
|
$1.29 Billion |
|
KSB SE & Co. KGaA
F:KSB3
|
$1.29 Billion |
|
Shanghai Pret Composites
SHE:002324
|
$1.29 Billion |
|
SNKCF
PINK:SNKCF
|
$1.29 Billion |
|
Zhuhai Orbita Control Eng
SHE:300053
|
$1.29 Billion |
|
Anhui Kouzi Distillery Co Ltd
SHG:603589
|
$1.29 Billion |
|
OXFORD INSTR. PLC LS-05
F:OX3
|
$1.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vitrolife AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,639,000,000 to 7,894,000,000, a change of -5,745,000,000 (-42.1%).
- Net loss of 4,712,169,709 reduced equity.
- Dividend payments of 140,058,496 reduced retained earnings.
- Other comprehensive income decreased equity by 1,675,000,000.
- Other factors increased equity by 782,228,205.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.71 Billion | -59.69% |
| Dividends Paid | $140.06 Million | -1.77% |
| Other Comprehensive Income | $-1.68 Billion | -21.22% |
| Other Changes | $782.23 Million | +9.91% |
| Total Change | $- | -42.12% |
Book Value vs Market Value Analysis
This analysis compares Vitrolife AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 14.86x to 0.31x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $1.21 | $18.00 | x |
| 2003-12-31 | $1.56 | $18.00 | x |
| 2004-12-31 | $1.64 | $18.00 | x |
| 2005-12-31 | $1.92 | $18.00 | x |
| 2006-12-31 | $2.23 | $18.00 | x |
| 2007-12-31 | $2.55 | $18.00 | x |
| 2008-12-31 | $2.96 | $18.00 | x |
| 2009-12-31 | $3.19 | $18.00 | x |
| 2010-12-31 | $3.33 | $18.00 | x |
| 2011-12-31 | $3.51 | $18.00 | x |
| 2012-12-31 | $2.84 | $18.00 | x |
| 2013-12-31 | $3.24 | $18.00 | x |
| 2014-12-31 | $7.01 | $18.00 | x |
| 2015-12-31 | $7.77 | $18.00 | x |
| 2016-12-31 | $9.38 | $18.00 | x |
| 2017-12-31 | $11.29 | $18.00 | x |
| 2018-12-31 | $13.75 | $18.00 | x |
| 2019-12-31 | $16.53 | $18.00 | x |
| 2020-12-31 | $18.54 | $18.00 | x |
| 2021-12-31 | $133.67 | $18.00 | x |
| 2022-12-31 | $123.61 | $18.00 | x |
| 2023-12-31 | $93.96 | $18.00 | x |
| 2024-12-31 | $100.61 | $18.00 | x |
| 2025-12-31 | $58.29 | $18.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vitrolife AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -136.98%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.41x
- Recent ROE (-59.69%) is below the historical average (16.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 104.58% | 112.80% | 0.55x | 1.69x | $105.36 Million |
| 2003 | 31.15% | 46.42% | 0.52x | 1.28x | $30.34 Million |
| 2004 | 7.93% | 11.49% | 0.56x | 1.23x | $-3.12 Million |
| 2005 | 8.42% | 12.37% | 0.57x | 1.20x | $-2.79 Million |
| 2006 | 6.89% | 8.87% | 0.63x | 1.23x | $-6.86 Million |
| 2007 | 14.23% | 19.08% | 0.63x | 1.18x | $10.72 Million |
| 2008 | 10.27% | 13.32% | 0.66x | 1.17x | $788.90K |
| 2009 | 10.95% | 12.42% | 0.76x | 1.15x | $2.96 Million |
| 2010 | 8.88% | 9.72% | 0.69x | 1.32x | $-3.64 Million |
| 2011 | 8.85% | 8.53% | 0.76x | 1.36x | $-3.94 Million |
| 2012 | 120.15% | 92.20% | 0.78x | 1.66x | $305.99 Million |
| 2013 | 17.53% | 12.43% | 0.93x | 1.52x | $24.18 Million |
| 2014 | 15.57% | 21.37% | 0.52x | 1.39x | $39.02 Million |
| 2015 | 21.69% | 25.31% | 0.68x | 1.26x | $98.53 Million |
| 2016 | 18.70% | 22.24% | 0.68x | 1.23x | $88.56 Million |
| 2017 | 21.51% | 25.20% | 0.74x | 1.16x | $141.05 Million |
| 2018 | 20.74% | 26.90% | 0.68x | 1.14x | $160.41 Million |
| 2019 | 21.34% | 25.86% | 0.69x | 1.19x | $203.38 Million |
| 2020 | 14.25% | 23.03% | 0.54x | 1.15x | $85.59 Million |
| 2021 | 2.23% | 20.29% | 0.09x | 1.27x | $-1.19 Billion |
| 2022 | 2.35% | 12.18% | 0.16x | 1.23x | $-1.28 Billion |
| 2023 | -30.27% | -109.65% | 0.22x | 1.28x | $-5.12 Billion |
| 2024 | 3.76% | 14.21% | 0.21x | 1.28x | $-850.90 Million |
| 2025 | -59.69% | -136.98% | 0.31x | 1.41x | $-5.50 Billion |
Industry Comparison
This section compares Vitrolife AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vitrolife AB (publ) (VTRLY) | $7.89 Billion | 104.58% | 0.41x | $1.29 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |